National Plan to Address Alzheimer's Disease: 2016 Update. Strategy 1.C: Accelerate Efforts to Identify Early and Presymptomatic Stages of Alzheimer's Disease

08/01/2016

Collaborating on Biomarker Research. One of the primary goals of the previously-noted AMP is to identify and characterize biomarkers and targets for intervention. The AMP-AD Biomarkers Project is a consortium of three NIA-supported Phase II/III secondary prevention trials testing several anti-amyloid therapies. Imaging and fluid biomarker panels already included in these trials will be supplemented with tau PET imaging and novel fluid biomarkers.

For more information, see:

________________________________________

Tracking Biomarker Trajectories Over Time. In late 2015, NIH launched a new initiative to identify biomarkers and track the progression of Alzheimer's in people with Down syndrome. The NIH Alzheimer's Biomarker Consortium-Down Syndrome is supporting teams of researchers using brain imaging, as well as fluid and tissue biomarkers, in research that may 1 day lead to effective interventions for all people with dementia. Costing an estimated $37 million over 5 years, the goal is to develop biomarker measures that signal the onset and progression of Alzheimer's in people with Down syndrome. Two research teams are working collaboratively to identify and track Alzheimer's-related changes in the brain and cognition of over 500 Down syndrome volunteers, aged 25 and older.

For more information, see:

________________________________________

Discovering Biomarkers for Alzheimer's Disease and Related Dementias. In addition to its ongoing support of several large collaborative projects and consortia that seek to discover biomarkers for FTD, NIH established two new biomarker efforts in 2015:

  • Small Vessel VCID Biomarkers Consortium will develop candidate biomarkers for small vessel disease in the brain.
  • NIH is soliciting longitudinal studies that would leverage the existing Parkinson's disease Biomarkers Program infrastructure to discover biomarkers for LBD.

     

For more information, see:

________________________________________